Dual ACE inhibitor (or ARB) and aliskiren treatment is also currently not recommended based on the results of the Aliskiren Trial In Type 2 Diabetes Using Cardio-Renal Disease Endpoints (ALTITUDE)27 which was prematurely ended as it did not demonstrate the benefit predicted by the initial protocol; safety issues also presented (i.e., increased incidence of stroke, kidney dysfunction, hyperkalemia and hypotension)28. Here, ACE is linked to Stroke.